Skip to Content

Thiotepa Dosage

Applies to the following strength(s): 15 mg ; 30 mg ; 100 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Breast Cancer

0.3 to 0.4 mg/kg by rapid IV administration once.

Usual Adult Dose for Ovarian Cancer

0.3 to 0.4 mg/kg by rapid intravenous administration once.

Usual Adult Dose for Serosal Cavity Neoplastic Disease

0.6 to 0.8 mg/kg by intracavitary injection once

Usual Adult Dose for Bladder Cancer

30 to 60 mg by intravesical instillation once, for the treatment of superficial bladder tumors

Usual Adult Dose for Lymphoma

500 to 1000 mg intravenously once, for the treatment of refractory lymphomas

Usual Adult Dose for Malignant Disease

0.3 to 0.4 mg/kg by rapid IV administration once.
or
0.6 to 0.8 mg/kg by intracavitary injection once.
or
0.6 to 0.8 mg/kg by intratumor injection once.
or
30 to 60 mg by intravesical instillation once.
or
10 to 15 mg by intrathecal injection once.
or
500 to 1000 mg IV once.

Usual Pediatric Dose for Malignant Disease

Sarcomas: 25 to 65 mg/m2 IV as a single dose every 3 to 4 weeks.

Autologous bone marrow transplantation: 300 mg/m2 IV over 3 hours, repeat every 24 hours for 3 doses. The maximum tolerated dose is 1125 mg/m2 over 3 days.

Renal Dose Adjustments

The manufacturer states that therapy is probably contraindicated in cases of existing renal damage. However, if the need outweighs the risk, thiotepa may be used in low dosage, accompanied by appropriate testing.

Liver Dose Adjustments

The manufacturer states that therapy is probably contraindicated in cases of existing hepatic damage. However, if the need outweighs the risk, thiotepa may be used in low dosage, accompanied by appropriate testing.

Dose Adjustments

In patients receiving intravenous administration, treatment should be discontinued if the white blood cell count is less than or equal to 3000/mm3 or if platelets are less than or equal to 150,000/mm3.

Precautions

The manufacturer states that therapy is probably contraindicated in cases of existing bone marrow damage. However, if the need outweighs the risk, thiotepa may be used in low dosage, accompanied by appropriate testing.

Dialysis

The manufacturer states that therapy is probably contraindicated in cases of existing renal damage. However, if the need outweighs the risk, thiotepa may be used in low dosage, accompanied by appropriate testing.

Other Comments

Dosages are calculate by actual body weight.

Dosages must be carefully individualized. Dosages of thiotepa may depend upon the specific indication for its use, and whether other cytotoxic agents are coadministered. Reference to specific protocols is recommended.

Intratumor injections can be mixed with 2% procaine or 0.1% epinephrine injection in order to decrease pain.

A slow response to thiotepa does not necessarily indicate a lack of effect. Therefore, increasing the frequency of dosing may only increase toxicity. After maximum benefit is obtained by initial therapy, it is necessary to continue the patient on maintenance therapy, generally at approximately 1 to 4 week intervals. The maintenance dose should be adjusted on the basis of pretreatment control blood count and subsequent blood counts. In order to continue optimal effect, maintenance doses should not be administered more frequently than once weekly, in order to preserve correlation between dose and blood counts.

Hide